Objective: The British Nutrition Foundation was recently commissioned by the Food Standards Agency to conduct a review of the government's research programme on Antioxidants in Food. Part of this work involved an independent review of the scientific literature on the role of antioxidants in chronic disease prevention, which is presented in this paper. Background: There is consistent evidence that diets rich in fruit and vegetables and other plant foods are associated with moderately lower overall mortality rates and lower death rates from cardiovascular disease and some types of cancer. The 'antioxidant hypothesis' proposes that vitamin C, vitamin E, carotenoids and other antioxidant nutrients afford protection against chronic diseases by decreasing oxidative damage. Results: Although scientific rationale and observational studies have been convincing, randomised primary and secondary intervention trials have failed to show any consistent benefit from the use of antioxidant supplements on cardiovascular disease or cancer risk, with some trials even suggesting possible harm in certain subgroups. These trials have usually involved the administration of single antioxidant nutrients given at relatively high doses. The results of trials investigating the effect of a balanced combination of antioxidants at levels achievable by diet are awaited. Conclusion: The suggestion that antioxidant supplements can prevent chronic diseases has not been proved or consistently supported by the findings of published intervention trials. Further evidence regarding the efficacy, safety and appropriate dosage of antioxidants in relation to chronic disease is needed. The most prudent public health advice remains to increase the consumption of plant foods, as such dietary patterns are associated with reduced risk of chronic disease.
In 2001, the British Nutrition Foundation was commissioned by the Food Standards Agency (FSA) to conduct a review of the government's research programme on Antioxidants in Food, which the Agency inherited from the Ministry of Agriculture, Fisheries and Food. The objective of the review was to set the findings of the government-funded research projects in an international context and to make recommendations about the future of the programme (the full report of this review is held in the FSA library). Part of this work involved summarising the epidemiological evidence for the so-called 'antioxidant hypothesis', which forms the basis of this paper.
The antioxidant hypothesis
A large number of epidemiological studies have shown that people who consume a diet with a high content of fruit and vegetables and other plant foods (e.g. nuts) are at reduced risk of developing cancer and cardiovascular disease (CVD) 1, 2 . Beneficial effects of such dietary patterns have also been reported for other chronic conditions. For example, inverse associations have been demonstrated between fruit and vegetable consumption and the risk of age-related macular degeneration (AMD) 3 , cataract 4, 5 and chronic obstructive pulmonary disease (COPD), including asthma and bronchitis 6, 7 . This has led to attempts to identify the specific components responsible for the health effects of these plant foods. A popular explanation, both within the scientific community and among members of the public, is that antioxidant nutrients, including vitamin C, vitamin E, the carotenoids (e.g. b-carotene, lycopene and lutein), selenium and the flavonoids (e.g. quercetin, kaempferol, myricetin, luteolin and apigenin), prevent carcinogenesis and atherogenesis by interfering passively with oxidative damage to DNA, lipids and proteins. Normal oxidative metabolism produces large amounts of potentially dangerous oxidants (free radicals) that can damage cells and tissues in a number of ways: damaging biomolecules and cell components, triggering the activation of specific signalling pathways, creating toxic products, altering gene expression and enzyme activity, and disrupting normal repair mechanisms 8 . Antioxidants prevent free-radical-induced tissue damage by preventing the formation of radicals, scavenging them or by promoting their decomposition. The disruption of the delicate balance between pro-and antioxidants is termed oxidative stress and has been implicated in the pathophysiology of many chronic diseases, including CVD, ageing, diabetes and cancer.
Antioxidants and CVD
Of all the diseases in which excess oxidative stress has been implicated, CVD has the strongest supporting evidence. Oxidation of low-density lipoprotein (LDL) cholesterol may be a key step in the development of atherosclerosis, a known risk factor in the development of CVD 9 . Oxidised LDL cholesterol is preferentially taken up by macrophages to create the foam cells characteristic of fatty streaks, which are precursors of atherosclerotic plaques. In addition, oxidised LDL cholesterol appears to be cytotoxic towards endothelial cells and to decrease the motility of tissue macrophages. Dietary antioxidants (particularly vitamin E, which is carried primarily in LDL cholesterol) may, therefore, provide protection by reducing the oxidation of LDL cholesterol and thereby slowing the development of atherosclerosis.
Although there are some exceptions, cross-sectional studies comparing different populations within one country or between different countries have found that the incidence of CVD, particularly in Europe, is inversely related to plasma levels of b-carotene, vitamin E (a-tocopherol) and, to a lesser extent, vitamin C 10, 11 . Countries with a very high prevalence of CVD, such as Scotland, Northern Ireland and Finland, have significantly lower plasma levels of vitamin E and b-carotene, while the Mediterranean countries have relatively higher blood levels and a lower incidence of CVD 12 . An ecological study based on middle-aged men from 16 different cohorts showed a similar inverse association between flavonoid intake and coronary mortality 13 , and increased rates of heart disease have also been reported in areas with low selenium status 14 . Some case -control studies have confirmed the same type of relationship at an individual level; for example, subjects with CVD have been shown to have lower levels of plasma vitamin E and selenium, compared with subjects without CVD 15 . Other studies have found lower leucocyte ascorbic acid concentrations in subjects with angiographic coronary artery disease compared with controls 12 and lower adipose tissue levels of b-carotene in patients with myocardial infarction (MI) compared with hospital-based controls 16 . Such studies, however, cannot exclude the possibility of alterations in nutritional status as a consequence of the disease or from subsequent lifestyle modifications.
More convincing evidence is provided by prospective studies in which nutrient status is measured years before the onset of the disease. Several large cohort studies have investigated the relationship between antioxidant nutrients in the diet or vitamin supplements and the incidence of CVD, and have generally demonstrated a trend towards decreasing risk of CVD incidence or mortality with higher dietary intake of vitamin E 17 -21 , b-carotene 22, 23 and vitamin C 24 and with higher plasma levels of these vitamins 25 -30 . Interestingly, findings of prospective studies that have investigated the role of vitamin supplements (predominantly in the USA) have been less convincing 20, 21, 31 . The results of prospective studies investigating the link between low selenium status/intake and heart disease have been mixed. Two of the studies that did find an association 32, 33 were conducted in Finland, where selenium intake has been very low until recently. For example, Salonen et al. demonstrated a 3.6-fold increase in coronary deaths and a 2.7-fold increase in heart attacks amongst men who had very low serum selenium status (, 45 mg l 21 ) 32 . In contrast, studies in populations with higher selenium intakes have not found an association 28,34 -36 . It is, therefore, conceivable that cardiovascular risk might be influenced only by very low selenium status 37 . A diet rich in flavonoids (mainly from onions, apples, tea and wine) has been inversely associated with subsequent CVD in some, but not all, prospective studies 38 
.
Evidence from intervention trials A number of large intervention trials for primary and secondary CVD prevention have now been conducted to try to demonstrate a causal relationship between vitamin C, vitamin E and b-carotene and CVD (Table 1) . The most positive results came from the Cambridge Heart Antioxidant Study (CHAOS), a controlled trial on 2002 heart disease patients with angiographically proven coronary atherosclerosis, randomly assigned to receive vitamin E or an inactive placebo 51 . The trial continued for almost 2 years. Vitamin E treatment significantly reduced the risk of CVD death and non-fatal MI combined (relative risk (RR) 0.53, 95% confidence interval (CI) 0.34 -0.83). However, the decrease was primarily due to a dramatic reduction in non-fatal MI and CVD deaths did not alter significantly. Other smaller trials have also demonstrated beneficial effects of antioxidant supplementation in groups of patients at high risk of oxidative stress. For example, in a trial of 196 haemodialysis patients with preexisting CVD who received 800 IU day 21 of vitamin E or matching placebo and were followed for a median of 519 days, a significant reduction was found in the primary endpoint (fatal or non-fatal MI, sudden death, ischaemic stroke, peripheral vascular disease or angina) amongst those who received the antioxidant supplementation (RR 0.54, 95% CI 0.33-0.89) 57 . In another randomised, .
A recent study has also demonstrated vitamin E supplementation to suppress restenosis in surgically induced atherosclerosis 59 . However, other secondary prevention trials have failed to detect any benefit of vitamin E or other antioxidant nutrients 52, 53, 56 . The Heart Protection Study examined the effect of a cocktail of antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C and 20 mg b-carotene) or placebo in over 20 000 UK adults (aged 40 -80 years) with coronary heart disease, other occlusive arterial disease or diabetes mellitus, who were supplemented for 5 years 56 . Although blood levels of antioxidant vitamins were substantially increased, no significant reduction in the 5-year mortality from vascular disease or any other major outcome was noted. In the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio) Prevenzione Trial, dietary fish oils reduced the risk of death, non-fatal MI and stroke in subjects with recent MI, but vitamin E supplementation (300 mg daily for 3.5 years) did not provide any benefit 52 .
Results of most primary prevention trials have also been unable to support the findings of the observational studies. For example, the Alpha Tocopherol Beta Carotene Prevention Study (ATBC) demonstrated no effect of b-carotene or vitamin E supplementation on the incidence of large abdominal aortic aneurysm 60 or on symptoms and progression of intermittent claudication 61 amongst men supplemented for an average of 6 years. The vitamin E supplement was associated with a reduction in cerebral infarction but a 50% increase in haemorrhagic stroke mortality 40, 41 . The net effect on all strokes was a small decrease in the incidence but a moderate (although insignificant) increase in mortality 41 . Supplemental b-carotene increased the incidence of cerebral hemorrhage 41 and led to an increase in deaths from MI 40 .
The published results of the SUpplementation en VItamines et Minéraux AntioXydants study (SU.VI.MAX) are still awaited. This is a randomised, double-blind, placebo-controlled, primary prevention trial in over 12 000 men and women in France, designed to test the efficacy of a cocktail of antioxidant vitamins and minerals, at nutritional doses, on premature death from CVD and cancer 48 . The study, which has been underway since 1994, involves supplementation with a combination of antioxidant nutrients (120 mg vitamin C, 30 mg vitamin E, 6 mg b-carotene, 100 mg selenium, 20 mg zinc) at doses around one to three times the daily recommended dietary allowances. Preliminary results presented at a recent scientific conference suggest that this regime has also demonstrated no effect on CVD risk (5th Congrès National de la Société Française d'Athérosclérose et de l'Arcol et de la Journée Nationale, June 2003). CVD -cardiovascular disease; GISSI -Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardio; MI -myocardial infarction; PUFA -polyunsaturated fatty acids; ACE -angiotensin-converting enzyme; CHD -coronary heart disease; NS -not significant.
* Secondary prevention is defined as including patients with known or documented vascular disease.
Systematic reviews and meta-analyses of the trials to date have, therefore, concluded that despite evidence from observational studies that people with a high occurrence of CVD often have low intakes or plasma levels of antioxidant nutrients, supplementation with any single antioxidant nutrient or combination of nutrients has not demonstrated any benefit for primary or secondary CVD prevention 62 -65 ( Fig. 1 ).
Antioxidants and cancer
The oxidative hypothesis of carcinogenesis asserts that carcinogens generate reactive oxygen species that damage RNA and DNA in cells, predisposing these cells to malignant changes. Oxidative damage to DNA occurs at a daily rate of 10 4 hits per cell in humans 66 .
Most, but not all, damage is corrected by internal surveillance and repair systems. Antioxidants are proposed to prevent cell damage by neutralising free radicals and oxidants, thus preventing subsequent development of cancer.
Case -control and cohort studies have consistently shown an inverse association between intake of carotenoids (a-carotene, b-carotene, lutein and lycopene) and risk of lung and stomach cancer 2, 67 . Comparing subjects in the highest category of dietary carotenoid intake with those in the lowest, risk reductions from 10 to 90% have been observed 68 . A number of prospective nested casecontrol studies have also shown an inverse association between high blood levels (usually of b-carotene) and subsequent risk of lung cancer (risk reductions of 40 -80% have been reported) 68 , with plasma b-carotene concentrations in the range of 0.34 to 0.53 mmol l 21 being associated with the lowest risk 69 . Most observational studies have also reported significant inverse associations between vitamin C intake and cancer risk 70 (risk reductions comparing the highest individual intake of vitamin C with the lowest have been between 10 and 70%) 68 . The most consistent data have been with non-hormone-dependent cancer sites of the oral cavity, larynx, pharynx and oesophagus, as well as of the lung, stomach, colon and rectum. Of the hormonedependent cancers, there is somewhat weaker evidence for a link with breast cancer 20, 71 but little evidence for any protective effect in ovary or prostate cancer. Data from nested case -control studies are limited, primarily because of the deterioration of this vitamin during frozen storage. However, two large studies have investigated the association. A 12-year follow-up of the NHANES II (National Health and Nutrition Examination Survey) cohort of US adults found men in the lowest serum ascorbate quartile to have a 62% higher risk of dying from cancer than men in the highest quartile, but found no association with cancer mortality in women 72 . Similarly, the UK arm of the European Prospective Investigation into Cancer and Nutrition (EPIC) found an inverse association between plasma ascorbic acid concentration and cancer mortality in men (a rise of 20 mmol l 21 in plasma ascorbic acid concentration was associated with a 21% reduction in risk, P , 0.02), but not women 30 .
Regions and countries with low selenium intakes or status have been shown to have higher rates of cancer death 73, 74 , and cancer patients have also been found to have lower concentrations of selenium in case-control studies 75, 76 , although these findings must be interpreted with care as blood levels have been shown to decline as disease progresses and patients with advanced disease tend to have lower blood selenium concentrations 76 .
Prospective studies have generally shown low selenium status to be associated with significantly increased risk of cancer incidence and/or mortality. The large Finnish Mobile Health Examination Survey showed a reduced risk of certain cancers, notably of the stomach and lung, in men 77 , and other prospective studies have shown an inverse association with risk of prostate cancer 78 and colorectal adenomas 79 . In contrast, most observational studies examining the relationship between dietary intake of vitamin E and risk of developing cancer have provided little evidence for a protective role of this vitamin. Around a third of studies measuring blood levels of vitamin E have shown that those with the highest levels have a lower risk of cancer (risk reductions observed have ranged from 20 to 80%) 68 , while the remainder have found no significant differences between cases and controls. Epidemiological data investigating the role of flavonoids in cancer prevention are scarcer and findings have been inconsistent. A prospective study of Finnish men and women found an inverse association between flavonoid intake and incidence of all sites of cancer combined following adjustment for many factors including intake of antioxidant vitamins 80 . This association was mainly a result of lung cancer, which presented a relative risk of 0.54 (95% CI 0.34 -0.87) in the highest compared with the lowest quartile of flavonoid intake. Intake of flavonols and flavones was also inversely associated with the risk of lung cancer (RR 0.56, 95% CI 0.5-0.69 in the highest vs. lowest quartile) but unrelated with any other type of cancer in the ATBC trials 81 . However, Hertog et al. demonstrated no association between dietary intake of the five major flavonoids and mortality from total cancer, lung cancer, colorectal cancer or stomach cancer in an analysis of data from the Seven Countries Study after 25 years of followup 13 or with mortality from cancer at all sites in the Zutphen Elderly Study 82 . In a more recent analysis of the same cohort, intake of catechins was found not to be significantly associated with the incidence of epithelial or lung cancer 83 . Therefore, despite plausible mechanisms, there is little observational evidence for any beneficial effect of flavonoids against cancer.
Evidence from intervention trials
The most positive findings from the randomised controlled trials to date were from the study in Linxian (China) in a rural population with poor nutritional status, where supplementation with a combination of b-carotene, selenium and vitamin E for 5 years led to a 21% reduction in stomach cancer mortality and a 13% reduction in total cancer mortality 39 (Table 2) . 40 . After 6 years of follow-up, b-carotene showed no protective effect on the incidence of any type of cancer 40,84 -86 . In fact, those randomised to receive this vitamin had an 18% higher risk of lung cancer (RR 1.18, 95% CI 1.03 -1.36) and an 8% higher total mortality than non-recipients. Subgroup analyses suggested that the adverse effect of b-carotene on lung cancer risk was restricted to heavy smokers 94 . This adverse effect was, however, lost on post-intervention follow-up 95 . The Beta Carotene and Retinol Efficacy Trial (CARET) was also terminated early because of similar findings; subjects receiving a combination of supplements (30 mg b-carotene and 25 000 IU vitamin A daily) experienced a 28% increased risk of lung cancer incidence (95% CI 1.07-2.00) 42 . Subgroup analyses also suggested that the effect was found in current, but not former smokers 42 . By contrast, in the Physicians' Health Study (PHS), supplementation of male physicians with 50 mg of b-carotene on alternate days had no effect on cancer incidence (men who were smokers did not experience any benefit or harm) 43 . The Women's Health Study terminated the b-carotene arm of the supplement interventions following the release of the CARET and PHS results 96 . The Heart Protection Study demonstrated no effect on 5-year cancer incidence or mortality from supplementation with 20 mg b-carotene in combination with 600 mg a-tocopherol and 250 mg vitamin C in individuals at high risk of CVD, despite increases in blood concentrations of these nutrients (plasma b-carotene concentrations rose four-fold) 56 . There is little evidence for any beneficial effects of supplementation with b-carotene for skin cancer prevention. The PHS found no effect after 12 years of b-carotene supplementation on the development of a first nonmelanoma skin cancer 87 . Two smaller trials have also supported this finding. Amongst 1621 men and women followed for 4.5 years (most of whom had no history of skin cancer at baseline), those randomised to supplementation with 30 mg b-carotene did not experience any reduction in risk of basal-cell or squamous-cell carcinoma 88 . The b-carotene supplement also had no influence on the occurrence of solar keratoses (a strong determinant of squamous-cell carcinoma) 97 . A 5-year trial of 1805 men and women with recent non-melanoma skin cancer also showed that supplementation with 50 mg b-carotene provided no protection against either type of skin cancer 91 , although this may have been because these cancers have a latency period of 12 years.
Together, these intervention studies have suggested that b-carotene supplements offer no protection against cancer and, amongst smokers, may actually increase the risk. Investigators have sought to explain these findings by proposing that under certain conditions b-carotene can have a pro-oxidant activity and act as a tumour promoter; high concentrations of antioxidants may shield DNA from oxidative damage, but could also protect 'initiated' cells from apoptosis and favour their clonal expression in tumour promotion 98 . Handelman et al. have suggested that b-carotene may be susceptible to oxidative damage from gases in cigarette smoke that may lead to the formation of harmful by-products 94, 99 . To date, there have been no published randomised controlled trials of vitamin C alone in primary prevention. However, data from the small number of trials investigating vitamin C in combination with other nutrients has not provided any support for a role for high-dose vitamin C supplementation in cancer prevention. The Linxian trial found no significant effect of supplementing a population of Chinese men and women with 120 mg vitamin C and 30 mg molybdenum daily for 5 years on the risk of cancer of the oesophagus or stomach 39, 100 . The Polyp Prevention Study found no evidence that either b-carotene or a combination of vitamin E and C (1000 mg) decreased the incidence of subsequent colorectal adenomas among 864 patients with previous adenoma 101 , and the Heart Protection Study also found no beneficial effects of supplementation with these three vitamins on cancer mortality 56 . However, Carr and Frei have suggested that the lack of any protective effect might be because dietary intake of vitamin C was already sufficient for tissue saturation, and highlight the need for further studies in people with low vitamin C intakes 102 . There is also limited evidence from intervention trials of any benefit from vitamin E in cancer prevention. The ATBC trial showed no significant effect of daily atocopherol supplementation (50 mg) on risk of lung 40 , pancreatic 94 , colorectal 84 or urinary tract 85 cancers amongst heavy smokers. However, in a post hoc subgroup analysis a 34% reduction in the risk of prostate cancer (RR 0.68, 95% CI 0.53-0.78) was seen in men who received this supplement 103, 104 and this reduction in risk was not demonstrated at post-intervention follow-up (6 years) 95 . Whilst these results are interesting, prostate cancer was not a primary endpoint of this study. No other studies have yet supported a preventative effect of vitamin E for prostate cancer. The Heart Protection Study found no effect of vitamin E in combination with vitamin C and b-carotene * Secondary prevention is defined as including patients with documented cancer including non-melanoma skin cancer (although some of the primary prevention trials did not exclude those with non-melanoma skin cancer at baseline).
on cancer incidence or mortality 56 . Two smaller, shortterm intervention studies found no effect of a-tocopherol supplementation on mammary dysplasia 105 or benign breast disease 106 . Several trials have also been unable to demonstrate a protective effect of vitamin E supplementation on the risk or recurrence of colorectal adenomatous polyps 98, 107, 108 . There is some evidence to support a protective effect of selenium supplementation on liver cancer in high-risk groups. The provision of selenium-fortified salt to a town in Qidong in China, where the inhabitants had high rates of primary liver cancer, reduced the incidence of this cancer by 35%, compared with towns that did not receive this intervention 109, 110 . Intervention trials have also demonstrated the incidence of liver cancer to be significantly reduced in subjects with hepatitis B 109, 111 , and amongst members of families with a history of liver cancer 109, 111 , receiving a daily supplement of 200 mg of selenium for 4 years and 2 years, respectively.
The main intervention trial conducted to date that supports a protective role of high selenium intake against cancer is a study of 1312 patients (mostly men) in the USA, with a previous history of skin cancer, supplemented either with placebo or 200 mg selenium per day. After 4.5 years, significant reductions in the risk of total cancer incidence (37%) and mortality (50%) were observed 92 . Whilst selenium was not found to have a protective effect against recurrent skin cancer, the selenium-treated group had substantial reductions in the incidence of lung, colorectal and prostate cancers, of 46%, 58% and 63%, respectively. Further analysis showed the protective effect on prostate cancer to be confined to those with lower baseline prostate-specific antigen and plasma selenium levels 112 . Although these data need confirmation, they suggest that adequate selenium intake might be important for cancer prevention.
A large European intervention trial, Prevention of Cancer by Intervention with Selenium (PRECISE), is being set up, which will be a 5-year study of the effect of selenium supplementation at different doses on the incidence of cancer in a normal healthy population 90 . Two pilot studies are currently underway, in the UK and in Denmark. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) in the USA will investigate the link between supplementation with selenium and vitamin E on the risk of prostate cancer. The SU.VI.MAX study has involved 7.5 years of supplementation with lower doses of a combination of antioxidant vitamins (120 mg vitamin C, 30 mg vitamin E, 6 mg b-carotene) and minerals (100 mg selenium, 20 mg zinc) than used in previous studies. Early reports suggest that this regime has led to a 31% and 37% reduction in cancer incidence and total mortality, respectively, compared with those receiving the placebo amongst men, but no benefit has been found amongst women (5th Congrès National de la Société Française d'Athérosclérose et de l'Arcol et de la Journée Nationale, June 2003). This inconsistent finding has been suggested to reflect higher dietary intakes of these nutrients amongst the women compared with the men in the study, but publication of these results is still awaited.
Antioxidants and COPD
The generation of oxygen free radicals by activated inflammatory cells produces many of the pathophysiological changes associated with COPD. Common examples of COPD are asthma and bronchitis, each of which affects large numbers of children and adults. Antioxidant nutrients have, therefore, been suggested to play a role in the prevention and treatment of these conditions. A number of studies have demonstrated a beneficial effect of fruit and vegetable intake on lung function 6, 7, 113 . For example, regular consumption of fresh fruit rich in vitamin C (citrus fruits and kiwi) has been found to have a beneficial effect on reducing wheezing, nocturnal cough and chronic cough in children 113 . Vitamin C is the major antioxidant present in the extracellular fluid lining the lung, and intake in the general population has been inversely correlated with the incidence of asthma 114 , bronchitis and wheezing 115 and with pulmonary problems 116 . Highdose supplementation (1 -2 g daily) has been shown to improve symptoms of asthma in adults 114 and protect against airway responsiveness to viral infections, allergens and irritants 117 . However, the beneficial effect of vitamin C has been attributed to the antihistaminic action of the vitamin rather than any antioxidant effect 69 . Other dietary antioxidants have also been positively associated with lung function. For example, decreased serum concentrations of a-tocopherol, b-carotene and vitamin C have been demonstrated in children with asthma, even during asymptomatic periods 118 . NHANES III, based on a large sample of 16 693 subjects, showed higher levels of several dietary antioxidant nutrients to be associated with better lung function in a healthy population. The combined effect on lung function of vitamin C, vitamin E, selenium and b-carotene (measured in diet and serum) was higher than for any vitamin studied alone 119 . In a study of 158 children with moderate to severe asthma, Romeiu et al. showed daily supplementation with vitamin E (50 mg) and vitamin C (250 mg) to lead to some improvement in lung function following ozone exposure 120 . However, the much larger ATBC trial found no benefit from supplementation with a-tocopherol (50 mg daily) and b-carotene (20 mg daily) on symptoms of COPD, despite those with high dietary intakes and blood levels of these vitamins at baseline having a lower prevalence of chronic bronchitis and dyspnea 121 . A small trial has investigated the effects of selenium supplementation in asthmatics. Those receiving the supplements experienced a significant increase in glutathione peroxidase levels and reported improvement in their asthma symptoms 122 . However, this improvement could not be validated by significant changes in the separate clinical parameters of lung function and airway hyper-responsiveness.
Antioxidants, macular degeneration and cataracts
The eye is at particular risk of oxidative damage due to high oxygen concentrations, large amounts of oxidisable fatty acids in the retina and exposure to ultraviolet rays. In Western countries, AMD is the leading cause of blindness among older people. Cataracts are also widespread among the elderly and occur when the lens is unable to function properly due to the formation of opacities within it. These develop when proteins in the eye are damaged by photooxidation; these damaged proteins build up, clump and precipitate. It has been proposed that antioxidants may prevent cellular damage in the eye by reacting with free radicals produced during the process of light absorption 123 . The carotenoids lutein and zeaxanthin are believed to be particularly important in preventing ocular damage because they are found in the pigment of the macular region of the normal retina, where they absorb blue light and protect against short-wavelength damage to the retina. A recent intervention study has shown that these carotenoids can be increased significantly by dietary supplementation 124 . Smokers who have lower plasma levels of carotenoids also have a lower macular pigment (lutein and zeaxanthin) density 125 and an increased risk of developing AMD 123 . Observational studies have examined the association between intake/plasma concentrations of antioxidant vitamins and AMD but the findings have been inconclusive and sometimes contradictory 126, 127 . The results of the limited number of intervention trials have also been variable. A study in the USA investigating the effects of combined antioxidant vitamins A, C and E (with and without zinc) showed some protective effect on the progression of moderately advanced AMD 128 . However, a recent intervention trial was unable to demonstrate any alteration in the incidence or progression of AMD following 4 years of daily supplementation with 500 mg vitamin E 129 . Recent Cochrane reviews have concluded that there is no evidence from randomised trials that healthy people should take antioxidant vitamin supplements to prevent the onset of AMD. However, on the basis of the US trial, an antioxidant and mineral supplement containing vitamin E, vitamin C, b-carotene and zinc may delay the progression of the disease in people with moderate to severe AMD 130 . Many studies have demonstrated the risk of cataracts to be inversely proportional to the serum level of antioxidants 131 -142 . A recent prospective study of dietary intake found that increased consumption of lutein and zeaxanthin reduces the risk of developing cataracts severe enough to require extraction 5 . The Beaver Dam Eye Study 134 did not show any strong link between five measured carotenoids and risk of cataracts but did show an inverse association with serum tocopherols 131 . In a cohort of women aged 45 -67 years, high dietary carotenoid intake was found to be associated with lower risk for cataract extraction 135 and in a cohort of US male health professionals, a significantly lower risk of cataracts was found with higher intakes of b-carotenerich foods 5 . Amongst a large group of American nurses, intake of vitamin C (but not of other antioxidants) was associated with a 69% reduction in the prevalence of lens opacities following adjustment for other nutrients 133 . Whilst the findings from these prospective studies have been encouraging, the results of intervention trials have been inconclusive. The Roche European American Cataract Trial (REACT), a randomised trial providing a combined daily supplement of b-carotene, vitamin C and vitamin E amongst adults with early signs of age-related cataract, showed a small deceleration in the progression of cataract after 3 years 136 . However, in the ATBC trial, men who were supplemented for 5-8 years with 50 mg of vitamin E or 20 mg of b-carotene or both showed no reduction in the prevalence of cataracts 137 . Moreover, a randomised, double-blind, placebo-controlled trial of over 22 000 male physicians aged 40-84 years showed no benefit from 12 years of supplementation with alternate daily b-carotene (50 mg) on the incidence of age-related cataract 138 . In fact, current smokers at the beginning of the study who received the supplement experienced an increased risk of cataract compared with the placebo group (RR 0.74, 95% CI 0.57-0.95).
Limitations of the cancer and CVD trials to date
Several reasons have been given to explain why the findings of the observational studies have differed from those of the large randomised trials. Clearly, nonrandomised studies are unable to exclude the possibility that antioxidants are simply acting as a surrogate measure of a healthy diet or lifestyle. However, while intervention studies provide a more rigorous source of evidence than observational studies, they are not without weaknesses from a nutritional perspective.
There has been discussion about the nature of the supplements used in the trials. First, most have used synthetic forms that may have different biological activity or potency from the natural forms of these vitamins (although trials using the natural forms have not suggested different clinical effects from those supplementing with synthetic forms 51, 53, 139 ). Second, concerns have been expressed about whether the correct carotenoid has been used (i.e. b-carotene vs. other carotenoids such as lycopene and lutein). However, a decline in blood concentrations of other carotenoids as a result of supplementation with b-carotene has not been observed in the supplementation studies 140 . Similarly, all of the trials investigating the effect of vitamin E supplementation have used a-tocopherol, the major form of vitamin E in human tissues, but this may lead to a decrease in plasma levels of g-tocopherol 141 . This is the most prevalent form of vitamin E in plant seeds and products derived therefrom, and contributes to the body's antioxidant defences 142 . Finally, single supplements may also interfere with the uptake, transport, distribution and metabolism of other antioxidant nutrients.
Most trials have tested the effect of high doses of one or two antioxidants, while the accumulation of mechanistic and epidemiological data suggests that antioxidants act not only individually but also co-operatively, and in some cases synergistically. An optimal effect would, therefore, be expected with a combination of nutrients at levels similar to those contained in the diet (corresponding to higher levels of intake associated with reduced risk in the observational studies) 143 . However, the effects of combinations of antioxidant vitamins or multiple antioxidants remain unclear. A small randomised trial in 160 patients with coronary disease, using a combination of antioxidant nutrients (800 IU a-tocopherol, 1000 mg vitamin C, 25 mg b-carotene and 100 mg selenium, twice daily) for 3 years, showed no benefit for secondary prevention of vascular disease 139 . Similarly, neither the Heart Protection Study 56 nor early reports from SU.VI.MAX support any effect of a cocktail of antioxidant nutrients on CVD risk, but the latter study has found a reduction in cancer risk amongst men (but not women) following supplementation with a number of antioxidant vitamins and minerals. Trials have not yet investigated other potentially beneficial nutrients in antioxidant-rich foods such as flavonoids and lycopenes.
Most of the intervention trials published to date (except the PHS) had durations of treatment and follow-up lasting only around 4-6 years. The conversion of an initiated cell to a pre-malignant or fully malignant cell is a lengthy process and can take decades. Cancer is, therefore, a disease that occurs over a long period of time, and the trials may have been too short to demonstrate any benefit. Steinberg has also hypothesised that, unlike agents that lower cholesterol or blood pressure, antioxidants may have to be used for more than 5 years to have demonstrable benefit on CVD, since the primary mechanism of these agents may be in the prevention of new lesions 144 . Many of the supplementation trials have not been undertaken on normal 'healthy' individuals but on those with pre-existing oxidative stress, either through smoking or pre-existing disease, amongst whom increasing antioxidant intake may not have been able to repair the oxidative damage process sufficiently to affect cancer or CVD risk. It is also possible that some unknown genetic factors (interacting with nutrition) may explain some of the lack of effect in intervention studies. A greater understanding of the impact of factors such as genotype, age and ill health on the interactions between antioxidants and reactive oxygen species would be of help in designing future trials.
The SU.VI.MAX study has taken account of many of these issues in its design and is testing the efficacy of supplementation amongst healthy subjects over an 8-year period with a cocktail of antioxidants at doses achievable by diet. This illustrates the type of nutritional approach that may be needed in the future. However, even if future trials do demonstrate a reduction in CVD or cancer risk with antioxidant supplementation, this cannot be attributed definitively to the antioxidant effect of these nutrients, as other biological functions may also play a role. For example, as well as retarding oxidation of LDL cholesterol, vitamin E may help to protect against CVD via its action on platelet aggregation and adhesion or by inhibition of the proliferation of smooth muscle cells. Furthermore, while vitamin C, vitamin E and selenium have been shown to decrease the concentration of some of the biomarkers associated with oxidative stress, the relationship between these biomarkers and chronic disease remains to be elucidated.
The intervention studies highlight the lack of information on the long-term safety of sustained intakes of moderate to high doses of micronutrient supplements. In particular, the finding of an increased incidence of lung cancer in people at high risk taking b-carotene supplements raises the possibility that a change in the usual balance of carotenoids in the diet (for instance, by high-dose purified supplements) might lead to potentially adverse perturbations in their absorption, metabolism or function. Such findings caution against the widespread use of moderate-to high-dose micronutrient supplements, which cannot be assumed to be without adverse effects 2 .
Conclusion
Although there is a substantial body of evidence that a diet rich in plant foods (particularly fruit and vegetables) conveys health benefits, as do high plasma levels of several antioxidant nutrients found in these foods, a causal link between lack of antioxidants and disease occurrence or between antioxidant administration and disease prevention remains to be established. There is a lack of understanding of the mechanisms underpinning the apparent protective effect of plant foods and, as yet, no clear picture of which components are effective, and hence no way of predicting whether all or just some plant foods are important in this respect. Further evidence is required regarding the efficacy, safety and appropriate dosage of antioxidants in relation to chronic disease. The most prudent public health advice continues to be to increase consumption of plant foods.
